首页|aMAP风险评分对乳腺癌的预后价值

aMAP风险评分对乳腺癌的预后价值

扫码查看
目的 探讨aMAP风险评分对乳腺癌的预后价值.方法 回顾性分析2013年1月-2016年12月驻马店市中心医院收治201例乳腺癌患者的临床病理资料.生存分析应用Kaplan-Meier和Log Rank方法.采用Cox比例风险模型分析乳腺癌的预后因素.结果 aMAP评分是乳腺癌术后的独立危险因素.低aMAP评分组患者乳腺癌术后DFS为73.41个月、OS为80.15个月,显著高于高aMAP 评分组(57.91、67.57 个月),差异有统计学意义(DFS:x2=7.662,P=0.006;OS:x2=7.026,P=0.008).结论 aMAP评分在预测乳腺癌的预后具有一定的价值,对于术前aMAP评分高的患者进行密切随访,可为乳腺癌的预后提供有力证据.
Prognostic value and clinical significance of aMAP risk score in breast cancer
Objective To explore the prognostic value and clinical significance of aMAP risk score for breast cancer.Methods This was a retrospective study of 201 breast cancer patients who received surgery in our hospital from January 2013 to December 2016.The survival curve were determined by Kaplan Meier and Log rank method.The multivariate COX proportional hazards model was used to an-alyze the prognostic factors after breast cancer surgery.Results The aMAP score was a potential prog-nostic factor by the multivariate analysis.The median disease free survival(DFS)(73.41 months vs.57.91 months)and overall survival(OS)(80.15 months vs.67.57 months)in low aMAP score group were longer than in high aMAP score group,and the difference was statistically significant(DFS:X2=7.662,P=0.0056;OS:X2=7.026,P=0.0080).Conclusion The aMAP score has certain value in predicting the prognosis of breast cancer,and aMAP score can provide strong evidence for the progno-sis of breast cancer.

Breast canceraMAP scoreAlbuminPlateletsPrognosis

郑伟

展开 >

驻马店市中心医院乳腺外科 河南驻马店 463003

乳腺癌 aMAP评分 白蛋白 血小板 预后

2024

华北理工大学学报(医学版)
河北联合大学

华北理工大学学报(医学版)

影响因子:0.569
ISSN:2095-2694
年,卷(期):2024.26(6)